Herpes simplex virus (HSV)-1 and HSV-2 cause painful blisters and shallow ulcers in exposed skin and mucosae during primary or recurrent infection. In addition, recurrent and potentially blinding HSV-1 infections of the eye afflict nearly half a million persons in the U.S. Current clinical therapies rely on nucleoside analog drugs such as acyclovir (ACV) or ganciclovir to ameliorate primary infections and reduce the frequency and duration of reactivations. However, these treatments do not fully suppress viral shedding and drug-resistant mutants develop in the eye and in vulnerable, immunosuppressed patients. Herpesvirus DNA replication requires several enzymes in the nucleotidyl transferase superfamily (NTS) that have recombinase and nuclease activities. We previously found that compounds which block NTS enzymes efficiently inhibit replication of HSV-1 and HSV-2 by up to 1 million-fold in Vero and human foreskin fibroblasts. Among the compounds with potent suppressive effects in culture is the anti-fungal drug ciclopirox. Here we report that topical application of ciclopirox olamine to the eyes of mice infected with HSV-1 reduced virus shed from the corneal epithelium compared with saline control, and reduced development of blepharitis to the level of mice treated with ACV. Results were dose-dependent. In addition, treatment with ciclopirox olamine significantly reduced acute and latent HSV-1 infection of the peripheral nervous system. These results support further development of ciclopirox olamine as a repurposed topical agent for HSV infections.
Introduction
Herpes simplex virus (HSV)-1 and HSV-2 cause much suffering and morbidity linked to a variety of diseases they perpetrate in infected persons (Whitley, 2001) . Painful blisters and shallow ulcers form in skin and mucosal surfaces of the mouth and genital tract at the site of penetrance and reoccur periodically throughout life from a latent reservoir in nerve ganglia innervating the initial site infection. Rarely, HSV may travel retrogradely into the central nervous system during primary or recurrent infection to cause clinically critical encephalitis. Recurrent HSV-1 infections of the eye afflict 400,000 persons in the U.S. (Farooq and Shukla, 2012; Lairson et al., 2003) , causing eyelid disease (blepharitis) and potentially blinding corneal keratitis (Azher et al., 2017) . Nucleoside analogs such as ACV or ganciclovir are in current clinical use to ameliorate primary infections with HSV-1, and decrease the duration and frequency of reactivations James and Prichard, 2014; King, 1988) . However, these treatments do not fully suppress viral shedding (Johnston et al., 2012; Vere Hodge and Field, 2013) . Furthermore, drug-resistant mutants develop in immunosuppressed patients (Andrei et al., 2000; Andrei et al., 2013; Field and Vere Hodge, 2013; Gilbert et al., 2002; James and Prichard, 2014; Schmit and Boivin, 1999) , and also in immunocompetent persons with recurrent eye infections (Burrel et al., 2013; Duan et al., 2008 Duan et al., , 2009 van Velzen et al., 2013) , and in healthy children (Wang et al., 2011) . A therapeutic option with a different mechanism of action than nucleoside analogs would be clinically useful.
HSVs replicate in epithelial cells at the site of initial penetrance before spreading into the nervous system. Herpesvirus DNA replication requires numerous viral enzymes (Weller and Coen, 2012) . Several of these enzymes have recombinase and nuclease activities consistent with members of the nucleotidyl transferase superfamily (NTS), including the pUL30 polymerase, pUL15 terminase, and the pUL12 nuclease which works in concert with the ICP8 single-stranded annealing protein (Bryant et al., 2012; Schumacher et al., 2012; Selvarajan et al., 2013; Weller and Coen, 2012) . NTS enzymes share a similar protein fold and enzymatic mechanisms including four conserved carboxylates that coordinate two divalent cations required to promote a hydroxyl-mediated nucleophilic scission reaction (Nowotny, 2009; Nowotny and Yang, https://doi.org/10.1016 /j.antiviral.2018 .06.010 Received 17 May 2018 Accepted 12 June 2018 2009). These enzymatic activities represent new potential targets for antiviral therapies. We previously found that compounds which block NTS enzymes efficiently inhibit replication of HSV-1 and HSV-2 by up to 1-million fold in Vero cells and human foreskin fibroblasts (Tavis et al., 2014) . Among the compounds with potent suppressive effects on HSVs in culture is the FDA-approved anti-fungal drug ciclopirox. Ciclopirox has an EC 50 against HSV-1 of 0.27 μM in Vero cells and a therapeutic index of > 185; these values are similar to ACV's EC 50 of 0.16 μM and therapeutic index of > 625 (Tavis et al., 2014) . Ciclopirox suppresses ACV-resistant (thymidine kinase-deficient) viruses, and time of addition experiments further suggest a different mechanism of action than ACV (Tavis et al., 2014) .
Ciclopirox olamine, the ethanolamine salt of ciclopirox, has long been known as an effective antimycotic, with broad-spectrum activity against dermatophytes, yeast, and filamentous fungi (Abrams et al., 1991; Bohn and Kraemer, 2000; Dittmar and Lohaus, 1973; Jue et al., 1985) . It gained FDA approval for topical applications such as dandruff, seborrhoeic dermatitis and onychomycosis (Subissi et al., 2010) . The potential to repurpose a drug already FDA-approved for topical use in a new antiviral indication is an exciting prospect. Here we provide evidence that topically applied ciclopirox olamine can reduce HSV replication and disease in a mouse model of corneal infection with HSV-1.
Materials and methods

Viruses, cells and compounds
Vero cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 3% newborn calf serum and 3% bovine growth serum (BGS), 2 mM L-glutamine and 1x penicillin-streptomycin (P/S) (Invitrogen). Stocks of HSV-1 KOS (Smith, 1964) and strain 17 (Brown et al., 1973) were propagated on Vero cells and titers were determined by standard plaque assay (Knipe and Spang, 1982) . Acyclovir (Sigma Aldrich) and ciclopirox olamine (Toronto Research Chemicals) were reconstituted in normal saline and working concentrations were prepared by dilution in normal saline just prior to use.
Animal studies
BALB/c mice, 6 wk of age, were purchased from Taconic Farms. They were handled in strict accordance with good animal practice as defined by Institutional and Public Health Service guidelines, and with work approved by the Institutional Animal Care and Use Committee. The animals were housed in the Saint Louis University School of Medicine Department of Comparative Medicine. Corneas of anesthetized mice were scarified as previously described (Morrison and Knipe, 1994) and infected by dropwise application of 1 × 10 4 pfu/eye HSV-1.
Swabs of the corneal surface were performed at various times post-infection and virus collected on them was quantified as previously described (Knipe and Spang, 1982) . At 4 d post-infection (acute) or 28 d post-infection (latent), mice were euthanized and trigeminal ganglia (TG) were dissected. For determination of latent viral genome load, DNA was isolated from TG using a QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's instructions.
Drug treatment
Mice were lightly anesthetized prior to each treatment using isofluorane. Drug was applied dropwise to the corneal surface in 4 μl vol and mice were maintained under isofluorane anesthesia another 3 min before being returned to their cage. Final concentrations of ciclopirox olamine were 3 μg/eye/dose and 1 μg/eye/dose (2.79 mM and 0.93 mM); ACV was administered at 4.5 μg/eye/dose and 1.5 μg/eye/dose (5 mM and 1.67 mM). Treatments were administered thrice per day for 4 d beginning 4 h post-infection.
Quantitative real-time PCR
The primers and Taqman probe for real-time PCR are specific for the HSV-1 LAT region. The primer sequences in ICP0 were: forward 5′-AGCCCCGTCTCGAACAGT-3'; reverse 5′-ACCACCATGACGACGA CTC-3'; and Universal Probe Library probe #56 was 5′-FAM-GGAGGTGdark quencher-3' (Roche). PCR reactions (25 μl vol) contained FastStart Universal Probe master mix containing Rox (Roche), and 1 μM forward and reverse primers, 250 nM probe, and 100 ng DNA template. Quantification was performed in triplicate using an ABI 7500 genetic analyzer (Applied Biosystems) with 1 cycle at 50°C for 2 min; 1 cycle at 95°C for 10 min; 40 cycles at 95°C for 20 s and 60°C for 1 min. Fortyfive to 1.8 × 10 5 copies of cesium chloride gradient-purified HSV-1 DNA were used to generate a standard curve. Data were analyzed using Sequence Detection System software (ABI) and expressed as HSV-1 genome equivalents per microgram total DNA.
Statistical analyses
Statistical significance of differences in titer of virus in TG, or of virus shed from the corneal surface was determined on individual days by ANOVA. The Kruskal-Wallis non-parametric test was used to analyze differences in blepharitis scores on individual days with Tukey's test for multiple comparisons. We compared qPCR results among groups using ANOVA with Bonferonni correction.
Results
Effect of ciclopirox on HSV-1 infection of the eye
Ciclopirox and ciclopirox olamine have equivalent EC 50 values against HSV in cultured cells (Tavis et al., 2014) , and unpublished observation. Before conducting in vivo efficacy studies, toxicity of ciclopirox olamine for the corneal epithelium was evaluated. Various doses of ciclopirox olamine were applied to the corneas of mice three times per day for 5 d, followed by inspection with an ophthalmoscope. Ciclopirox olamine at 3 μg/eye/dose was selected as a non-toxic maximal dose and a lower dose of 1 μg/eye/dose was also used to assess dose-responsiveness. ACV at 4.5 μg/eye/dose was used as a positive control because it was previously demonstrated to be effective in reducing HSV-1 replication in the cornea (Willey et al., 1991) . A 3-fold lower dose of 1.5 μg/eye was also used.
Groups of BALB/c mice were infected on the scarified corneas with 1 × 10 4 pfu of HSV-1 KOS. Ciclopirox olamine, ACV or saline was then applied to the corneal surface three times per day for 5 d beginning 4 h post-infection. Corneal swabs taken between doses of drug revealed that the higher doses of ACV and ciclopirox controlled virus replication in the corneal epithelium better than application of saline days 1 through 5 post-infection (Fig. 1) . The suppressive effect was dose-dependent because neither the lower dose of ciclopirox olamine nor ACV reduced HSV-1 replication compared with saline control. By day 7 virus replication in all groups had declined. Signs of blepharitis over time post-infection were extremely mild in mice treated with either 4.5 or 1.5 μg/eye ACV compared with saline. Similarly, the higher dose of ciclopirox olamine provided significant protection from blepharitis (Fig. 2) . However, the protective effect was lost at the lower dose of ciclopirox. Differences in keratitis could not be assessed because this dose of HSV-1 KOS caused minimal corneal disease even in mice treated with saline (data not shown). Weight of the mice was also assessed daily post-infection as an indicator of overall health, and although all treatment groups lost less weight than the control group no significant differences between treatment groups was observed (data not shown). Lastly, the effect of drugs on latent infection of the TG was assessed 28 d post-infection by qPCR. TG of KOS-infected mice treated with saline contained large numbers of latent viral genomes (Fig. 3) . Markedly fewer viral genomes were detected in TG of mice treated with low and high doses of ciclopirox olamine or ACV, though the lower dose of ciclopirox was slightly less effective. Thus, ciclopirox olamine treatment of the cornea can reduce HSV-1 replication in the epithelium, eyelid disease, and latent infection.
Effect of ciclopirox treatment on infection with a more virulent HSV-1 strain
HSV-1 KOS is considered a strain of relatively low virulence (Dix et al., 1983; Luker et al., 2006) . To determine whether ciclopirox olamine would inhibit replication of a different strain of HSV-1, we infected groups of mice with 1 × 10 4 pfu of HSV-1 strain 17 and subsequently treated them with the higher dose of ciclopirox olamine, ACV, or with saline only. Both drugs again significantly suppressed HSV-1 replication in the cornea compared with the control group (Fig. 4A) . To determine whether acute infection of the nervous system was affected by drug treatment, we quantified viral genomes in the TG 4 d postinfection. Mice treated with saline contained a large number of viral genomes in the TG (Fig. 4B) . In contrast, ciclopirox and ACV markedly reduced the number of viral genomes detectable at this early time postinfection. Thus, ciclopirox treatment also protects mice against acute infection with a more virulent HSV-1 strain. 
Discussion
We have demonstrated that topical treatment with ciclopirox olamine reduces HSV-1 replication in the cornea, acute and latent infection of the nervous system, and development of blepharitis. The effect of both ACV and ciclopirox on replication of HSV-1 KOS is dose-dependent. Whether ciclopirox reduces infection of the nervous system solely because of its impact on replication in the cornea is unknown, but this is unlikely given that low dose ciclopirox appeared to have a disproportionately large effect on accumulation of latent genomes (compare Figs. 1 and 3) . Pharmacokinetic experiments have demonstrated that ciclopirox olamine can be detected in the corneas and TG of mice treated orally with a single high dose and is maintained there for 4 h post-treatment (data not shown). The finding that ciclopirox enters the peripheral nervous system suggests the possibility that ciclopirox may directly suppress virus replication in the TG, either after uptake into axons from the treated cornea or via the bloodstream. Thus, ciclopirox may have the potential, even when applied topically, to reduce HSV infection of the nervous system.
The reduction in blepharitis observed in drug-treated mice is likely due to ciclopirox suppression of acute infection in the eye and TG because blepharitis is largely the result of virus spread from the TG to the eyelid (Summers et al., 2001 ). This reported mechanism underlying development of blepharitis is consistent with our observation that disease did not occur until 5 d or more post-infection, a time when infection of the cornea is declining rapidly. In contrast to the higher dose of ciclopirox, the lower dose had no effect on acute replication in the cornea. Although the differential impact of high dose versus low dose ciclopirox on subsequent infection of the nervous system is small (Fig. 3) , the difference may become magnified as virus mounts a return trip to the eyelid.
Anti-inflammatory effects of ciclopirox were demonstrated in a topical application to the mouse ear (Abrams et al., 1991; Hanel et al., 1991; Liebel et al., 2006) . Consistent with this report, we did not observe an increase in angiogenesis in the cornea (data not shown). However, HSV-1 KOS caused only mild effects on the cornea, including induction of keratitis, which prevents us from drawing a definitive conclusion in this regard. It will be of interest to test ciclopirox formulated in ophthalmic ointment for effectiveness and anti-inflammatory effects, and conceivably a higher non-toxic dose of ciclopirox could be achieved.
The mechanism by which ciclopirox/ciclopirox olamine reduces HSV replication is not yet known. Its antifungal activity appears to result from disruption of cell membrane integrity or function (Bohn and Kraemer, 2000; Jue et al., 1985) . In bacteria, ciclopirox potently inhibits respiration (Bohn and Kraemer, 2000; Jue et al., 1985) . Ciclopirox reduces HIV replication (Hanauske-Abel et al., 2013) by inhibiting synthesis of the rare amino acid hypusine, thereby preventing formation of mature, hypusine-containing eIF5A needed for HIV transcription initiation (Hoque et al., 2009) . Ciclopirox also chelates iron and has been shown to inhibit the iron-dependent ribonucleotide reductase enzyme (Eberhard et al., 2009) . Although HSV also expresses a ribonucleotide reductase, the enzymatic function is not essential in dividing cells and thus its potential suppression is unlikely to be the sole contributor to inhibition of HSV replication. More likely, ciclopirox interferes with the function of one or more viral NTS enzymes. Thus, the inhibitory effects of ciclopirox on HSV replication may be via direct antiviral or indirect activities.
Microbial resistance to existing drugs is a growing clinical concern. Nucleos(t)ide analog-resistant HSV mutants develop in up to 6.4% of immunocompetent individuals (Piret and Boivin, 2011) and up to 36% of immunocompromised individuals with herpetic eye disease (Andrei et al., 2000; Field and Vere Hodge, 2013; Gilbert et al., 2002; James and Prichard, 2014; Schmit and Boivin, 1999) . We have found that ciclopirox olamine powerfully suppresses ACV-resistant mutants of HSV-1 and HSV-2 in tissue culture (Tavis et al., 2014 ). It will be interesting to determine whether ciclopirox synergize with ACV since it has a different apparent mechanism of action (Tavis et al., 2014) . The fact that ciclopirox olamine has FDA approval for topical use suggests exciting potential for repurposing this antifungal drug as an anti-herpesviral medication.
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